Neomorph entered multi-target collaboration and licensing agreement with Novo Nordisk for molecular glue degraders in cardiometabolic and rare diseases. Total deal value up to $1.46B across multiple targets, plus upfront, R&D funding, and tiered royalties. Neomorph leads discovery and preclinical work with Novo Nordisk holding exclusive clinical and commercialization rights.